Free Trial
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Taysha Gene Therapies logo
$2.40 -0.03 (-1.23%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.48 +0.08 (+3.13%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Key Stats

Today's Range
$2.39
$2.49
50-Day Range
$1.80
$2.93
52-Week Range
$1.05
$3.31
Volume
726,725 shs
Average Volume
2.93 million shs
Market Capitalization
$515.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20
Consensus Rating
Buy

Company Overview

Taysha Gene Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

TSHA MarketRank™: 

Taysha Gene Therapies scored higher than 64% of companies evaluated by MarketBeat, and ranked 317th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Taysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Taysha Gene Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Taysha Gene Therapies is -7.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Taysha Gene Therapies is -7.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Taysha Gene Therapies has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Taysha Gene Therapies' valuation and earnings.
  • Percentage of Shares Shorted

    16.11% of the float of Taysha Gene Therapies has been sold short.
  • Short Interest Ratio / Days to Cover

    Taysha Gene Therapies has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Taysha Gene Therapies has recently increased by 4.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Taysha Gene Therapies does not currently pay a dividend.

  • Dividend Growth

    Taysha Gene Therapies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.11% of the float of Taysha Gene Therapies has been sold short.
  • Short Interest Ratio / Days to Cover

    Taysha Gene Therapies has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Taysha Gene Therapies has recently increased by 4.03%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Taysha Gene Therapies has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.
  • Search Interest

    Only 9 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 3.78% of the stock of Taysha Gene Therapies is held by insiders.

  • Percentage Held by Institutions

    77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Taysha Gene Therapies' insider trading history.
Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

TSHA Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

TSHA Stock Analysis - Frequently Asked Questions

Taysha Gene Therapies' stock was trading at $1.73 at the beginning of the year. Since then, TSHA shares have increased by 38.7% and is now trading at $2.40.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The firm earned $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative trailing twelve-month return on equity of 104.93%.
Read the conference call transcript
.

Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

Last Earnings
5/15/2025
Today
7/07/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
180
Year Founded
2020

Price Target and Rating

Average Stock Price Target
$8.20
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+241.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$89.30 million
Net Margins
-1,201.08%
Pretax Margin
-1,201.08%

Debt

Sales & Book Value

Annual Sales
$8.33 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
6.86

Miscellaneous

Free Float
206,548,000
Market Cap
$515.18 million
Optionable
Optionable
Beta
0.97

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TSHA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners